T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership position in Medpace Holdings Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 1,136,251 shares of Medpace Holdings Inc. common stock.
  • Percent of class: The 1,136,251 shares represent 4.1% of the outstanding class, which the filing designates as ownership of 5 percent or less of a class.
  • Sole voting power: T. Rowe Price reported sole voting power over 1,105,129 shares, with 0 shares subject to shared voting power.
  • Sole dispositive power: The firm reported sole dispositive power over all 1,136,251 beneficially owned shares, with 0 shares subject to shared dispositive power.
  • Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA"), organized in Maryland, with its principal office at 1307 Point Street, Baltimore, MD 21231.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.

T. Rowe Price Associates Discloses Amended Medpace Holdings Position

T. Rowe Price Associates, Inc. submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Medpace Holdings Inc. (CUSIP 58506Q109), according to the filing. The document was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., and dated November 16, 2026. The triggering event date for the amended disclosure is September 30, 2026.

According to the filing, T. Rowe Price beneficially owns 1,136,251 shares of Medpace Holdings Inc. common stock, equaling 4.1% of the class. Of that total, the firm holds sole voting power over 1,105,129 shares and sole dispositive power over the full 1,136,251 shares. No shares are reported as subject to shared voting or shared dispositive power. The filing notes that Item 5 applies, designating this as ownership of 5 percent or less of a class.

The filing includes a certification stating that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further states that "T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." Medpace Holdings Inc. is headquartered at 5375 Medpace Way, Cincinnati, OH 45227, as listed in the filing.

What Was Disclosed

T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 1,136,251 shares, or 4.1%, of Medpace Holdings Inc. common stock as of September 30, 2026, with sole dispositive power over all reported shares.